|
|
Post by JHam on Jul 14, 2014 17:31:26 GMT
|
|
|
|
Post by JHam on Jul 14, 2014 17:31:56 GMT
|
|
|
|
Post by JHam on Jul 14, 2014 19:05:54 GMT
Not to stir a can of worms again, but this part from the PR is interesting:
In competition with Geron, the Singapore-based company ES Cell International and Cell Cure Neurosciences Ltd also built key assets and were later acquired as subsidiaries of BioTime. In addition, after leaving Geron in 1998, Dr. West led the competing company Advanced Cell Technology from 1998-2005 and after coming to BioTime he licensed certain other key patent applications from ACT. These included compositions and methods for deriving more than 200 purified lineages of cells, a technology known as "PureStem®" (US Patent number 8,685,386) as well as US Patent number 8,753,884 which describes an important and broad pathway of making all human cell types without ever creating or using human embryonic or induced pluripotent stem cells.
|
|
|
|
Post by dayanand33 on Jul 14, 2014 20:15:55 GMT
Legitimacy of Patent claims is one thing that is extremely hard to grasp ( "slide to unlock-apple", "single click checkout- Amazon"). It is hard to predict the ultimate winner. Therefore it is best to spread out risk in a basket of stem cell stocks.
|
|
|
|
Post by brnhut on Jul 14, 2014 20:31:32 GMT
Can-o-worms indeed! No way a forum thread can create the full picture of how patent infringement proceedings would carry! To oversimplify my understanding of the patent situation, for a patent to be enforceable in its jurisdiction, it must be conceived and reduced to practice before it will be heard.
|
|
|
|
Post by davidconrad on Aug 14, 2014 18:38:03 GMT
Off the top of my head. These patents from ACTC licensed to Biotime are for a type of SCNT. They can be retained by ACTC for a fee of $5000. This technology is about 4 years from a Phase 1 human trial. This technology is thought to be less robust than the single cell blastomere technology that ACTC is running with. From what I've read, it is not on the verge of being competitive as a commercial entity.
|
|
